VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

SABCS 2020 | Immune oncology in breast cancer: KEYNOTE-086, NCI 10013, & AIPAC

Sangeetha Reddy, MD, UT Southwestern Medical Center, Dallas, TX, discusses the latest updates in immune-oncology as presented at this year’s virtual San Antonio Breast Cancer Symposium (2020). Dr Reddy summarises three abstracts, relating to the KEYNOTE-086 study (NCT02447003) evaluating pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer, a National Cancer Institute (NCI) study evaluating carboplatin and paclitaxel with or without atezolizumab before surgery in patients with newly diagnosed triple-negative breast cancer, and finally, the AIPAC randomized Phase IIb study (NCT02614833) evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor-positive metastatic breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter